Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
A Time of Careful Eating: Individual Tests in Nourishment- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Which Countries Would Suffer Most in a Global Energy Shutdown? This Study Has Answers
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- FDA approves Wegovy pill for weight loss
- Moon memorial: Artemis 2 astronauts name lunar 'bright spot' after mission commander's late wife
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals
